Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Octreotide capsule is a novel, orally-administered formulation of the commercially-available
injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated
maintenance of biochemical response up to 13 months in the majority of patients with
acromegaly previously managed with somatostatin analog injections (reference below).